A new analysis of the phase 3 ARCHES trial suggests that a simple clinical model may help predict which men with metastatic hormone-sensitive prostate cancer are most likely to achieve a very deep PSA response after starting treatment with an androgen-receptor pathway inhibitor. The model, called NADIR, was designed to estimate the probability of reaching […]
Platinum chemotherapy is not usually considered a standard targeted treatment for metastatic prostate cancer, but the phase 2 CIPHER trial suggests that carboplatin may have meaningful activity in men with mCRPC carrying homologous recombination repair (HRR) mutations. The study enrolled 39 patients with HRR-altered mCRPC who had already received at least one androgen-receptor pathway inhibitor […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Another promising week for us! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Clinical Research Phase 2 Trial: ENV105 Combined with Apalutamide in […]
Neuroendocrine prostate cancer is one of the most aggressive forms of the disease and remains particularly difficult to treat. A new Oncogene study has identified a possible mechanism that helps these tumours suppress the immune response, centred on a molecule called Neuromedin U, or NMU. In mouse models of neuroendocrine prostate cancer, the researchers found […]
CAR-T therapy has transformed some blood cancers, but solid tumors remain much more difficult. One major problem is tumor heterogeneity: not every cancer cell expresses the same target, and tumours can change over time. A new preclinical study published in Cancer Immunology Research describes a way to make CAR-T cells more adaptable. The researchers created […]
B7-H3 has become one of the most interesting targets in advanced prostate cancer, especially for antibody-drug conjugates and other targeted treatments. A new Cancer Discovery study suggests that B7-H3 may not simply sit on the surface of tumour cells: it may actively help the cancer suppress the immune system and resist treatment. The researchers found […]
A new phase 2 trial will test JNJ-101556143, also known as HLD-0915, in men with metastatic prostate cancer that has become resistant to androgen-pathway treatment. The study plans to enrol about 100 patients and will evaluate whether the drug can produce objective tumour responses, making this a clear step beyond the earlier dose-finding programme. JNJ-101556143 […]
A new first-in-human phase 1 trial, has been posted for JUR-003 in metastatic prostate cancer. The study plans to enrol up to 210 patients and includes dose-escalation and dose-expansion cohorts in mCRPC, metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease. JUR-003 will be given intravenously, with the initial goals of defining safety, pharmacokinetics and a […]
A new 2026 review proposes an interesting idea: bipolar androgen therapy (BAT) may help make prostate cancer more sensitive to PARP inhibitors, even in some tumours that do not carry the classic BRCA1/2 mutations usually associated with strong PARP responses. BAT exposes prostate cancer cells to rapid swings between very high and very low testosterone […]
We already discussed ENV105 (carotuximab) in a previous ProstateWarriors article, when the safety lead-in of its phase 2 trial in metastatic castration-resistant prostate cancer was completed. Since then, the programme has produced its first meaningful efficacy signal, making it worth revisiting. ENV105 targets CD105, a protein that appears to become more active as prostate cancer […]